## **PGY2 Oncology Program Director and Coordinators**



## Amanda N. Seddon, PharmD, BCPS, BCOP

**Director, PGY2 Oncology Pharmacy Residency** 

Assistant Professor of Pharmacy Practice
Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy

#### **Rotations:**

Hematology Stem Cell Transplant and Cellular Therapy Outpatient Stem Cell Transplant Clinic Inpatient Medical Oncology Benign Hematology

### **Education:**

Doctor of Pharmacy: University of Illinois at Chicago College of Pharmacy

## **Residency:**

PGY1: University of Illinois Hospital and Health Sciences System PGY2 Oncology: Memorial Sloan Kettering Cancer Center

#### **Publications:**

https://scholar.google.com/citations?hl=en&user=tGN8DYkAAAAJ

## **Professional Organization Affiliations and Leadership:**

- ASTCT: Pharmacy SIG, Communications and Membership Recognition –
   Immediate Past Chair (2020-Present), Chair (2019-2020), Chair-Elect (2018-2019), Member (2017-Present)
- HOPA: BCOP Preparatory/Review Course Task Force Member (2018-Present),
   Standards Committee Member (2018-Present), BCOP Item Writing Task Force

- Member (2017-2018)
- ICHP: Residency Leaders Network and Public Education and Awareness Outreach Publication Subcommittee – Member (2020-Present)
- Affiliations: AACP, ACCP Heme/Onc PRN, ASTCT, ASCO, HOPA, ICHP, Phi Lambda Sigma National Leadership Society

#### **Practice Interests:**

Stem cell transplant, cellular therapy, AML, lymphoma, breast cancer



## Becca Myers, PharmD, BCOP

Project Coordinator, PGY2 Oncology Pharmacy Residency
Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy

## **Rotations:**

Hematology Stem Cell Transplant and Cellular Therapy Outpatient Stem Cell Transplant Clinic Inpatient Medical Oncology Benign Hematology

### **Education:**

Doctor of Pharmacy: Midwestern University Chicago College of Pharmacy Bachelor of Science in Zoology: University of Wisconsin Madison

## Residency:

PGY1: Indiana University Health

PGY2 Oncology: Indiana University Heath Simon Cancer Center

### **Publications:**

■ Tollkuci E, Fitzpatrick P, Seddon AN, **Myers R**, Nathan S, Ustun C. Biosimilar Infliximab Administration for the Management of Acute Graft-Versus-Host

Disease. J Oncol Pharm Practice 2020; (0)1-5.

- Myers RA, Wirth S, Williams S, Kiel PJ. Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia. J Adv Pract Oncol 2018;9(4):435-440.
- Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab, Oncogene 30. 2011 February 3;561-574.
- Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos K, Chunrong L, Peet C, Wheeler DL. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biology & Therapy. 2011 September 1;12(5): 436-46.

## **Professional Organization Affiliations and Leadership:**

Affiliations: APSHO, ASTCT, ASCO, HOPA, ICHP

#### **Practice Interests:**

CNS lymphoma, leukemia, oncologic emergencies, infectious complication in HSCT, precision genomics



## Eris Tollkuci, PharmD, BCOP

Presentation Coordinator, PGY2 Oncology Pharmacy Residency

Assistant Professor of Pharmacy Practice
Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy

#### **Rotations:**

Hematology Stem Cell Transplant and Cellular Therapy Outpatient Stem Cell Transplant Clinic Inpatient Medical Oncology Benign Hematology

## **Education:**

Doctor of Pharmacy: University of Illinois at Chicago College of Pharmacy Pre-pharmacy coursework: Elmhurst College

## **Residency:**

PGY1: Rush University Medical Center

PGY2 Oncology: Rush University Medical Center

#### **Publications:**

- https://scholar.google.com/citations?hl=en&view\_op=list\_works&gmla=AJsN-F7MERrtF8H1VVLLY7dxzKX\_1VdTSGcBJoac7qO3Gorg7lhcmsbJdhNwbvyG\_Ueb7U2gWXlsTAaYjgbAzFJdrhtG0QX\_mA&user=GykWCeAAAAAJ
- **Tollkuci E**. Immune checkpoint inhibitor toxicity management. *HOPA News*. (Publication anticipated June 2020)
- Yun D H, Varma A, Santos C A, Tollkuci E, Nathan S, Ustun C. Lethal candida blankii infection in a recipient of allogeneic hematopoietic stem cell transplantation. Submitted to *Emerging Infectious Diseases*. (Publication anticipated June 2020)
- **HELIX magazine** "Dr. Eris Tollkuci on shaping the next generation of pharmacists". April 13, 2020. https://www.rosalindfranklin.edu/news/dr-eristollkuci-on-shaping-the-next-generation-of-pharmacists/
- **Tollkuci E**, Chalmers A, Schultz K, Dewdney S, Basu S, Usha L. Clinical outcomes using carboplatin desensitizations in patients with gynecologic cancer. *Journal of Hematology Oncology Pharmacy*. 2020;10(2):65-72.
- Tollkuci E. Contributor. The basics of immune checkpoint inhibitors for non-oncology healthcare providers. HelixTalk Episode #111. 2020 April 6. https://www.rosalindfranklin.edu/academics/college-of-pharmacy/helixtalk/helixtalk-episode-111-the-basics-of-immune-checkpoint-inhibitors-for-non-oncology-healthcare-providers/
- Tollkuci E. Fertility Preservation: An important consideration prior to malignancy treatment. ACTA Scientific Women's Health. 2020;2.2:01.

- ASTCT: Pharmacy SIG, Education Committee Member (2020-Present)
- ECOG ACRIN: Steering Committee Member (2020-Present)
- HOPA: Patient Outreach Committee Member (2017-Present)
- Journal of Oncology and Pharmacy Practice (JOPP) and Women's Health
   Manuscript Reviewer <a href="https://publons.com/researcher/1264167/eris-tollkuci/">https://publons.com/researcher/1264167/eris-tollkuci/</a>
- Affiliations: AACP, ASTCT, ASCO, HOPA, ICHP

#### **Practice Interests:**

Stem cell transplant, cellular therapy, leukemia, medication safety, aGVHD, infectious complications in HSCT, immunotherapy and targeted therapies

## **PGY2 Oncology Program Preceptors – Core Rotations**



## Mildred Carino, PharmD, BCOP

Clinical Pharmacy Specialist, Hematology/Oncology

#### **Rotations:**

Outpatient Hematology/Oncology Clinic

#### **Education:**

Doctor of Pharmacy: University of Illinois at Chicago College of Pharmacy Bachelor of Science in Biology and Art History: University of Illinois at Chicago

## **Residency:**

PGY1: University of Chicago Medicine

PGY2 Oncology: University of Chicago Medicine

#### **Publications:**

Formerly Mildred Vicente

- Vicente M, Al-Nahedh M, Parsad S, Knoebel RW, Pisano J, Pettit NN. Impact of a clinical pathway on appropriate empiric vancomycin use in cancer patients with febrile neutropenia. *J Oncol Pharm Pract*. 2017;23(8):575-581.
- Kang Y, Vicente M, Parsad S, Brielmaier B, Pisano J, Pettit N. Evaluation of Risk Factors for Vancomycin Resistant Enterococcus Bacteremia Among Previously Colonized Hematopoietic Stem Cell Transplant Recipients. Trans Inf Dis 2013 Oct; 15(5):466-73.
- Vicente M. Denosumab Expanded Indications for Cancer Treatment-Induced Bone Loss (CTIBL) Due to Hormone Ablation Prostate and Breast Cancer. HOPA Newsletter. 2012. Volume 9, Issue 1.

Affiliations: HOPA, ACCP

#### **Practice Interests:**

Lymphoma, gynecology/oncology, sarcoma, breast cancer, lung cancer, hospice and palliative care, supportive care oncology, oral chemotherapy, clinical informatics



## Trevor Christ, PharmD, BCOP

**Clinical Pharmacy Specialist, Hematology/Oncology** 

#### **Rotations:**

Outpatient Hematology/Oncology Clinic Pharmacogenomics Infusion Center Pharmacy

#### **Education:**

Doctor of Pharmacy: University of Illinois at Chicago College of Pharmacy Bachelor of Science in Biochemistry: Bradley University

## **Residency:**

PGY1: University of Chicago Medicine

PGY2 Oncology: University of Chicago Medicine

## **Publications:**

https://scholar.google.com/citations?view\_op=list\_works&hl=en&user=bKdDoIEAA AAJ&gmla=AJsN-F7nu1A5h176\_V3o-cpgVbmE9BIVmlkmd4CG3z0LGp7 LcbQweO3H-3MNF-9ED8MaHVFPXndXHxgDMO\_xMFQkocecEuF2-q2ZqxUdQ izA3Tjbh4Zk0TOBFuCSyV\_kIYwVkr\_F3mFu

Affiliations: HOPA

#### **Practice Interests:**

Precision oncology, gastrointestinal cancers



## Melika Fini, PharmD, BCOP

**Clinical Pharmacy Specialist, Hematology/Oncology** 

#### **Rotations:**

Outpatient Hematology/Oncology Clinic

### **Education:**

Doctor of Pharmacy: University of North Carolina Eshelman School of Pharmacy Bachelor of Science in Biochemistry: University of Illinois at Urbana-Champaign

## **Residency:**

PGY1: University of Illinois Hospital and Health Sciences System PGY2 Oncology: Froedtert & the Medical College of Wisconsin

## **Publications:**

- Fini M, McGurty E. Utilizing Digital Patient Engagement to Support the Management of Oral Anticancer Therapy. HOPA News. Volume 16, Issue 1. March 2019.
- Fini M, Yan CH, Touchette DR, Stranges PM. Cost-effectiveness of office-based medication-assisted treatment for opioid use disorder in United States. J Am Coll Clin Pharm 2018;1(2):122-353. doi: https://doi.org/10.1002/jac5.1059

## **Professional Organization Affiliations and Leadership:**

Affiliation: HOPA

#### **Practice Interests:**

**Breast cancer** 



## Justin Fisher, PharmD

Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy

### **Rotations:**

Hematology Stem Cell Transplant and Cellular Therapy Outpatient Stem Cell Transplant Clinic Inpatient Medical Oncology Benign Hematology

#### **Education:**

Doctor of Pharmacy: The Ohio State University, College of Pharmacy Bachelor of Arts in Biology and Music: Western Reserve University

## **Residency:**

PGY1: Rush University Medical Center

PGY2 Oncology: Northwestern Memorial Hospital

## **Publications:**

- Click ZR, Seddon AD, Bae YR, Fisher JD, Ogunniyi A. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia. Pharmacotherapy. 2018;38(11):1143-54.
- Engle JP, Dick TB, Bryant G, Ciolek A, Crismon ML, Fisher JD, Lasota S, Newsome AS, Thrasher K, Vest MH, Ward J. Credentialing and privileging for clinical pharmacists. J Am Coll Clin Pharm. 2020;3:133-44.

- ACCP: Certification Affairs Committee
- Affiliation: ASTCT, ICHP, ACCP

#### **Practice Interests:**

Targeted therapies in AML, prevention/treatment of GVHD, infectious complications after SCT, CAR T-cell therapy, immunotherapy toxicity management



# Nanette Gamazon Masangcay, PharmD, BCPS

**Cancer Center Clinical Trials Pharmacist** 

#### **Rotations:**

**Investigational Drug Services** 

#### **Education:**

Doctor of Pharmacy: University of Illinois at Chicago College of Pharmacy

## **Residency:**

PGY1: Loma Linda University

## **Practice Interests:**

Hematology/oncology, clinical trials, pediatrics



## Kristen Garcia, PharmD

**Clinical Pharmacy Specialist, Hematology/Oncology** 

### **Rotations:**

**Investigational Drug Services** 

## **Education:**

Doctor of Pharmacy: Palm Beach Atlantic University
Bachelor of Science in Diagnostic Genetic Sciences: University of Connecticut

## **Residency:**

PGY1: Jesse Brown VA Medical Center

## **Professional Organization Affiliations and Leadership:**

Affiliation: HOPA

### **Practice Interests:**

Research



## Niveen Hilal, PharmD

## Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy

#### **Rotations:**

Hematology Stem Cell Transplant and Cellular Therapy Outpatient Stem Cell Transplant Clinic Inpatient Medical Oncology Benign Hematology

#### **Education:**

Doctor of Pharmacy: University of Illinois at Chicago Bachelor of Arts in English Literature: University of Illinois at Chicago

## **Residency:**

PGY1: University of Chicago Medicine PGY2 Oncology: University of Chicago Medicine

### **Publications:**

 Gilmartin C, Barton A, Hughes D, Hilal N. (January 2016). Risky business: Lessons from medication misadventures in chronic kidney disease. Physician Assistant Clinics. 1:55-76.

## **Professional Organization Affiliations and Leadership:**

Affiliations: ACCP, ASHP, HOPA

#### **Practice Interests:**

B-ALL in AYA population, precision oncology, infectious complications in immunocompromised hosts, targeted therapy in AML



## Danielle Murphy, PharmD

Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy

### **Rotations:**

Hematology Stem Cell Transplant and Cellular Therapy Outpatient Stem Cell Transplant Clinic Inpatient Medical Oncology Benign Hematology

## **Education:**

Doctor of Pharmacy: Midwestern University Chicago College of Pharmacy

## **Residency:**

PGY1: Spectrum Health Hospital

PGY2 Oncology: The Ohio State University James Cancer Center and Solove


Research Institute

## **Professional Organization Affiliations and Leadership:**

Affiliations: APhA, ASHP, ASTCT, HOPA

### **Practice Interests:**

Hematology, bone marrow transplant



## Brian Seyboth, PharmD, BCOP

Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy

### **Rotations:**

Hematology
Stem Cell Transplant and Cellular Therapy
Outpatient Stem Cell Transplant Clinic
Inpatient Medical Oncology
Benign Hematology

### **Education:**

Doctor of Pharmacy: University of Rhode Island, College of Pharmacy

## **Residency:**

PGY1: Maine Medical Center

PGY2 Pediatric Oncology: Memorial Sloan Kettering Cancer Center

#### **Publications:**

https://scholar.google.com/citations?user=PpOUWLcAAAAJ&hl=en&oi=ao

## **Professional Organization Affiliations and Leadership:**

Affiliation: ASTCT

## **Practice Interests:**

Stem cell transplant, cellular therapy, bone marrow failure disorders

Not pictured: Laura Gleason, PharmD, BCOP

## **PGY2 Oncology Program Preceptors – Elective Rotations**



# Sally Arif, PharmD, BCPS, BCCP

**Clinical Pharmacy Specialist, Cardiology** 

## **Rotations:**

Cardiology-oncology

#### **Education:**

Doctor of Pharmacy: The University of Kansas School of Pharmacy

## **Residency:**

PGY1: Inova Fairfax Hospital

PGY2 Internal Medicine: Indiana University Health

#### **Publications:**

https://scholar.google.com/citations?user=-RvfY\_EAAAAJ&hl=en

## **Professional Organization Affiliations and Leadership:**

- AACP Health Disparities and Cultural Competency SIG Chair
- ACCP Cardiology and Global Health PRN member
- American College of Cardiology member

## **Practice Interests:**

Chemotherapy-induced cardiac disease, atrial fibrillation, heart failure



## Megan Britton, PharmD, BCPS

**Clinical Pharmacy Specialist, Specialty Oncology Pharmacy** 

### **Rotations:**

Oral chemotherapy clinic

#### **Education:**

Doctor of Pharmacy: University of Illinois at Chicago College of Pharmacy

Bachelor of Science: Illinois State University

## **Residency:**

PGY1: University of Illinois Hospital and Health Sciences System
PGY2 Critical Care: Midwestern University Chicago College of Pharmacy/Rush
University Medical Center

## **Publications:**

Formerly Megan Prasse

- Rech M, Prasse M, Gurnani P (2012). Alternative Therapies for Septic Shock: Beyond Early Goal-Directed Therapy, Severe Sepsis and Septic Shock -Understanding a Serious Killer, Dr Ricardo Fernandez (Ed.), ISBN: 978-953-307-950-9, InTech, DOI: 10.5772/29212.
- Rech MA, Prasse M, Patel GP. Use of Vasopressors in Septic Shock. JCOM. 2011; 18:273-277.
- University of Illinois at Chicago Drug Information Group. Prasse M. What is the cross-reactivity of cephalosporins and carbapenems in a patient with a penicillin allergy? Frequently Asked Questions March 2010. <a href="http://dig.pharm.uic.edu/faq/penicillin.aspx">http://dig.pharm.uic.edu/faq/penicillin.aspx</a>.
- **Prasse H**, & Prasse M. (2007, Winter). Bisphosphonate therapy: Is it taken for granted? Our Central Line, 15, 1.
- Gatto C, Helms JB, **Prasse M**, Huang S, Zou X, Arnett K, Milanick M. Similarities

- and Differences between Organic Cation Inhibition of the Na,K-ATPase and PMCA. Biochemistry, 45 (44), 13331 -13345, 2006.
- Gatto C, Helms JB, Prasse M, Arnett K, Milanick M. Kinetic characterization of tetrapropylammonium inhibition reveals how ATP and Pi alter access to the Na+-K+-ATPase transport site. Am J Physiol Cell Physiol, August 2005; 289: C302-C311.
- Milanick MA, Arnett AL, Helms JB, Prasse M, and Gatto C. Differential size exclusion between the inside and outside facing cation sites of the Na,K-ATPase (Abstract). Biophys J 86: 495a, 2004.

Affiliations: ASHP, SCCM

#### **Practice Interests:**

Specialty pharmacy, oral oncolytics (breast cancer, neuro-oncology, gynecology oncology)



# Hayley Hodgson, PharmD, BCIDP

**Clinical Pharmacy Specialist, Infectious Disease** 

### **Rotations:**

Infectious Disease

#### **Education:**

Doctor of Pharmacy: University of Georgia College of Pharmacy

## **Residency:**

PGY1: Rush University Medical Center

PGY2 Infectious Diseases: Midwestern University Chicago College of Pharmacy/

**Rush University Medical Center** 

#### **Publications:**

- Hodgson H, Sim T, Gonzalez H, Aziz M, Rhee Y, Lewis PO, Shields B, Wang SK. Successful treatment of cerebral toxoplasmosis using pyrimethamine oral solution compounded from inexpensive bulk powder. *Open Forum Infect Dis*. 5.4 (2018): ofy055.
- Hodgson H, Gandhi AS, Clark SM. Role of pharmacist interventions in the safe administration of anti-CD20 monoclonal antibodies. *J Hematol Oncol Pharm*. December 2018.

## **Professional Organization Affiliations and Leadership:**

Affiliations: ACCP, SIDP, IDSA

### **Practice Interests:**

Gram-negative resistance mechanisms, COVID-19 therapeutics, antimicrobial stewardship, penicillin allergy de-labeling

## Christy Varughese, PharmD, BCIDP

**Clinical Pharmacy Specialist, Infectious Disease** 

## **Rotations:**

Infectious Disease

#### **Education:**

Doctor of Pharmacy: Massachusetts College of Pharmacy

Master of Science: Rush University

## **Residency:**

PGY1: Rush University Medical Center

PGY2 Infectious Diseases/Solid Organ Transplant: Yale New Haven Hospital

## **Publications:**

https://www.researchgate.net/scientific-contributions/2057689586\_Christy\_ Varughese

## **Professional Organization Affiliations and Leadership:**

Affiliation: ACCP

## **Practice Interests:**

Invasive fungal infections, multi-drug resistance, antimicrobial stewardship

Not pictured: Michael Yannell, PharmD, MBA, BCPS

## **PGY2 Oncology Program Preceptor – Longitudinal Experience**



## Kathryn Schultz, PharmD, BCPS, BCOP

Clinical Pharmacy Specialist, Hematology/Oncology/Cell Therapy Manager, Adult Inpatient Oncology & Internal Medicine

### **Rotations:**

Policy/management

### **Education:**

Doctor of Pharmacy: Midwestern University Chicago College of Pharmacy Bachelor of Science in Biology (Cell and Molecular): Winona State University

## **Residency:**

PGY1: Rush University Medical Center

PGY2 Oncology: University of Michigan Hospitals and Health Centers

### **Publications:**

- Tollkuci E, Chalmers A, **Schultz K**, Dewdney S, Basu S, Usha L. Clinical outcomes using carboplatin desensitizations in patients with gynecologic cancer. *Journal of Hematology Oncology Pharmacy*. 2020;10(2):65-72.
- **Schultz K**. Chemotherapy symptom management: Helping each patient with their journey. *Pharmacy Tech Topics*. 2016;21:1-35.
- Janusek M, DiGrazia L, Schultz K, Geswein L, Crank C, Fung H. Neutropenia recovery linked to filgrastim initiation timing after autologous hematopoietic stem cell transplantation. *Journal of Hematology Oncology Pharmacy*. 2016;6:12-16.
- Peksa G, Schultz K, Fung H. Dosing algorithm for concomitant administration of sirolimus, tacrolimus and an azole after allogeneic hematopoietic stem cell

transplantation. Journal of Oncology Pharmacy Practice. 2015;21:409-15.

- Chang L, Frame D, Braun T, Gatza E, Hanauer DA, Zhao G, Magenau JM, Schultz K, Tokala H, Ferrara JLM, Levine JE, Paczesny S, Reddy P,Choi SW. Engraftment Syndrome following allogeneic hematopoietic cell transplantation predicts poor outcomes. Biology of Blood and Marrow Transplant. 2014;20:1407-17.
- **Schultz K.** Optimizing outcomes in patients with follicular lymphoma. *Considerations in Lymphoma*. 2011;3(2):16-19.
- Schultz K and Mackler E. Therapies for MRSA in cancer patients. The Oncology Pharmacist. 2009;

## **Professional Organization Affiliations and Leadership:**

- HOPA Public Policy Committee Vice Chair
- ICHP Division of Government Affairs Member

#### **Practice Interests:**

Technology/Informatics, quality improvement, public policy, supportive care